Monopar Therapeutics: Robinson proposes sale of 29,056 shares
The transaction detail ties the shares to an option exercise and lists an approximate sale date of September 24, 2026.
Rhea-AI Filing Summary
Monopar Therapeutics Inc. is named as issuer for Chandler Robinson’s proposed sale of 29,056 common shares, with an aggregate market value of $2,597,025.28. The approximate sale date is September 24, 2026; Morgan Stanley Smith Barney LLC is listed as broker and NASDAQ as the exchange. Acquisition details identify an exercise of stock options from the issuer and list cash.
Positive
- None.
Negative
- None.
Key Figures
Proposed shares for sale: 29,056 common shares
Aggregate market value: $2,597,025.28
Issuer shares outstanding: 6,712,172 shares
3 metrics
Proposed shares for sale
29,056 common shares
Approximate sale date: September 24, 2026
Aggregate market value
$2,597,025.28
Proposed common-share sale
Issuer shares outstanding
6,712,172 shares
Securities information
Key Terms
Rule 144, Exercise of Stock Options
2 terms
Rule 144 regulatory
"paragraph (a) of Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Exercise of Stock Options financial
"Exercise of Stock Options"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.